Immune Therapies Flashcards

1
Q

what is the main reason for immune therapies

A

therapeutic benefit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what 3 things promote protective immune responses

A

vaccination

fight tumours

treat immunocompromised patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what conventional and targeted immune therapies are used to suppress unwanted immune responses

A

chronic inflammation

autoimmunity

allergy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

4 reasons why we vaccinate

A

Most effective strategy to prevent infectious disease
- Second to clean drinking water

Promote human health

Primary aim to induce immunity in individuals
- Vaccines given to healthy people to keep them healthy

Successful programmes protect entire communities and populations
- E.g. eradication of small pox

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what 6 vaccines are included in the UK six in one vaccine

A

Pertussis (whooping cough)

Diphtheria

Tetanus

Polio

Hib

Hepatitis B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

pertussis

A

whooping cough

bacterial disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

tetanus

A

life threatening muscle spasms

from deep cut/animal bite

booster every 10 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

polio

A

virus affecting nervous system

  • paralysis
  • can be asymptomatic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Hib

A

bacterial – severe infection, sepsis, meningitis, pneumonia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

12 diseases protected against by UK vaccination programme

A

Pertussis (whooping cough)

Diphtheria

Tetanus

Polio

Hib

Hepatitis B

MenB and MenC

Rotavirus

Pneumococcal conjugate vaccine (PCV)

measles, mumps, rubella (MMR)

seasonal flu

human papilloma virus (HPV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is key to national immunisation programmes effectiveness

A

public trust

need to maintain high % vaccinated in population to keep rates low

vaccines are safe and effective but not completely risk free
- adverse effects can occur

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

evolution of immunisation

A

Disease is increasing

Vaccine increase
- Disease fall

Increase in perceived or real adverse events

  • public awareness of vaccine diminish
  • Not seeing disease thus not aware of risks associated with disease
  • Risk of immunisation with vaccine will decrease as cannot see side effects of disease

Outbreaks can increase awareness of disease risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

herd immunity

A

to have complete protection from exposure need 95% coverage of the vaccine in the population to keep levels low

MMR need 2 doses to be effective

ethical dilemma - should vaccines be made compulsory

  • lose autonomy
  • protection of greater good
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

how do vaccines work

A

Replicate immunity from natural infection without illness

Replicate adaptive immunity and generate long-term immunological memory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

induction of protective long term immunity

A

Epithelial barrier cuts
- Skin, Respiratory tract

Adaptive Immunity
- Engulf pathogen
Degrade it and present bits of pathogen on surface

T cells recognise part of antigen
- Proliferate and different into effective t cells

B cell recognise pathogen

  • B activation
  • —Make IgM antibodies
  • —Non specific
  • —Not that effective at clearing infection

Need an activated effector T cell to help B cell

  • B cell can differentiate to plasma cell
  • Antibody class switching
  • —High affinity IgG antibodies
  • —Effective at clearing infection

Have small population of long-lived memory cells
- respond immediately next time, not take 7-10 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

induction of highly specific antibody to natural infection is key becuase

A

No Adaptive immunity
- Time for B cells and IgM
—–Takes longer to get B and T cell talk to have class switching
- Then make IgG
—–Sufficiently high affinity to clear infection
Most plasma cells die - some remain

Production of high affinity IgG cells first is quicker as of innate immune memory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what is the most important goal for vaccination

A

Production of high affinity IgG represents the most important goal of vaccination
try and generate memory

No adaptive immunity
straight to innate immune memory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

primary response by immune system to disease

A

Low specificity IgM produced first

High specificity IgG takes longer
- Requires T cell help

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

secondary response by immune system to disease

A

More rapid

More effective

High specificity IgG produced by long-lived plasma cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

vaccination aims to

A

reproduce immunity to natural infections without causing disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

vaccination involves

A

exposing our immune system to disease causing microbial antigens but without causing disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what are virulence factors

A

are the molecules expressed by bacteria that help them attach, invade and replicate within our tissues

basically, they are disease-causing factors and these are the bits of microbes that stimulate our immune system
- recognises virulence factors as non-self antigens

and if those virulence factors are conserved structural components – such as bits of Gram negative cell wall (LPS) or Gram positive cell wall (peptidoglycan) or even viral RNA then they are recognised by and activate our innate immune response

but if they specific for a particular pathogen – e.g. a specific receptors expressed by the chicken pox virus or a bacterial toxin – they will activate our adaptive immune response.

So, our immune response has to encounter the disease causing factors in order to mount an immune response
the dilemma then is how to expose the immune system to those disease-causing factors without causing disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

what does our immune response recognise virulence factors as

A

recognises virulence factors as non-self antigens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

how are virulence factors that are conserved structural components recognised as

A

conserved structural components – such as bits of Gram negative cell wall (LPS) or Gram positive cell wall (peptidoglycan) or even viral RNA

then they are recognised by and activate our innate immune response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

what are conserved structural component

A

such as bits of Gram negative cell wall (LPS) or Gram positive cell wall (peptidoglycan) or even viral RNA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

how are virulence factors that are specific to antigens recognised by immune system

A

specific for a particular pathogen (e.g. a specific receptors expressed by the chicken pox virus or a bacterial toxin)

they will activate our adaptive immune response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

example of virulence factor that are specific to antigens

A

e.g. a specific receptors expressed by the chicken pox virus or a bacterial toxin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

what is the dilemma in designing a vaccine

A

how to expose the immune system to those disease-causing factors without causing disease

29
Q

3 types of vaccine

A

live attenuated

inactivated

subunit (purified antigen)

30
Q

what are the 4 types of subunit (purified antigen) vaccine

A

Recombinant

Toxoid

Polysaccharide

Conjugate

31
Q

live attenuated vaccines

A

Live but weakened via genetic manipulations

Capable of replication within host cells

Excellent life-long immunity

Potentially pathogenic in immune-compromised

E.g. MMR, BCG, Rotavirus

32
Q

inactivated vaccines

A

Killed through chemical or physical processes but still structurally intact

Cannot replicate or cause disease
- safer

Weak immunity

Several doses required - boosters

e.g. Polio, Pertussis

33
Q

subunit (purified antigens) vaccines

A

No live components
- Take proteins or peptides

Recombinant – produced by genetic engineering

  • Hep B
  • HPV

Toxoid – inactivated bacterial toxins

  • Diphtheria
  • Tetanus

Polysaccharide
Capsule on outside of cell membrane - encapsulated bacteria
- Helps bacteria evade and hide from immune system
T cell-independent – activated not in response to peptides?

Conjugate

  • Recruit B cells to talk to T cells to get high IgG
  • –polysaccharide antigens linked to proteins

PCV/Hib/Men-C

34
Q

recombinant subunit (purified antigen) vaccine

A

produced by genetic engineering

  • Hep B
  • HPV
35
Q

toxoid subunit (purified antigen) vaccine

A

inactivated bacterial toxins

  • Diphtheria
  • Tetanus
36
Q

polysaccharide (purified antigen) vaccine

A

Capsule on outside of cell membrane - encapsulated bacteria
- Helps bacteria evade and hide from immune system
T cell-independent – activated not in response to peptides?

37
Q

conjugate (purified antigen) vaccine

A

Recruit B cells to talk to T cells to get high IgG
—polysaccharide antigens linked to proteins

PCV/Hib/Men-C

38
Q

IgG response to live attenuated vaccines

A

One dose of vaccine can generate a high specificity IgG response
- Typically still get 2

39
Q

IgG response to inactivated/subunit vaccines

A

Weaker immunity

Takes 2 or 3 doses
- For long live memory response

40
Q

what is an adjuvant

A

Enhance immune responses to vaccine antigens

Inactivated/subunit vaccines

Aluminium/calcium salts

  • Maintain and prolong antigen stability
  • Enhance and prolong antigen presentation
  • Granuloma formation

Intramuscular delivery

41
Q

5 routes of vaccine administration

A

Intramuscular – most common
- Hep B, Hib, PCV-7

Subcutaneous
- measles, yellow fever

Intradermal - scaring
- BCG

Intranasal

Oral
- OPV, rotavirus

42
Q

background aetiology to dental caries

A

Bacterial aetiology

Cariogenic bacteria produce acids that demineralise tooth surfaces

  • Dietary sugars as energy source
  • Ferment by anaerobic metabolism
  • Make acid as by product
  • Demineralise tooth surface

Mutans streptococci

  • Extremely efficient at accumulating and producing carious surfaces
  • —Preferred binding site
  • —Colonisation stimulates immune system – antibodies made for them
  • Extremely tolerant of low pH
  • Colonisation coincides with tooth eruption
  • Colonisation stimulates specific IgA and IgG
43
Q

biological considerations for dental caries vaccine (block colonisation of Mutans streptococci)

A

Mutans streptococci dominate environments frequently exposed to dietary carbohydrates

Mutans streptococci are not the only-cariogenic bacteria in the oral biofilm
- Other cariogenic species are likely to fill niche

44
Q

ethical considerations for dental caries vaccine (block colonisation of Mutans streptococci)

A

Non-life threatening condition

Expensive

Other initiatives are more cost-effective

  • Childsmile
  • Water fluoridation
  • Dietary advice
45
Q

key reason against periodontal disease vaccine

A

polymicrobial

- Target one could lead to competitive advantage for others to fill niche

46
Q

what does the decrease in Communicable diseases being main cause of death lead to

A

increase in aging population

increase in burden of non-communicable diseases

  • Cardiovascular diseases
  • Cancer
  • Metabolic disorders
  • Chronic kidney diseases
  • Autoimmune diseases
  • Neurodegenerative disorders
47
Q

successful vaccination programmes have contributed to

A

Decreasing burden of infectious diseases

Increasing burden of NCDs associated with aging

48
Q

what underlies most chronic diseases that dominate present dat morbidity and mortality

A

pathological inflammatory pathways

- inflammation responses to infection and other challenges body faces

49
Q

4 conventional immunosuppressive drugs

A

Corticosteroids

Non-steroidal anti-inflammatories (NSAIDS)

Methotrexate (DMARDs)

Biological therapies

50
Q

corticosteroids are

A

Synthetic versions of cortisol e.g. prednisolone
- stress hormone, released in flight or fight response

Non-specific anti-inflammatory function

51
Q

corticosteroids effect

A

Treat wide range of inflammatory/allergic conditions
- Wide spread anti-inflammatory effect

Systemic or topical application

52
Q

4 side effects of corticosteroids

A

weight gain

risk of infection

risk of diabetes

risk of hypertension

53
Q

NSAIDs

A

non-steroidal anti-inflammatory drugs

ibuprofen, aspirin

54
Q

mechanism of NSAIDs

A

Upregulate COX2

Absorbed through stomach
- Take food, don’t take on empty stomach

55
Q

effects of NSAIDs

A

Reduce pain, inflammation and fever

Constant use can lead to gastro-intestinal bleeding, liver and kidney problems

Interact with other medications (warfarin, diuretics, methotrexate)

56
Q

methotrexate aka

A

Disease-modifying anti-rheumatic drug (DMARD)

57
Q

high doses of DMARD

A

chemotherapy agent

58
Q

low doses of DMARD

A

inflammatory arthritis treatment

59
Q

effect of DMARD (methotrexate)

A

Multi-faceted anti-inflammatory effects
- Often one of first drugs given

Slows progression of arthritis
- Don’t know how they mediate these effects

Can be combined with biological therapies

60
Q

biological therapies (biologics)

A

Genetically engineered antibodies made from human genes

Directly target specific components of immune system to inhibit activity

  • B-cell inhibitor (Rituximab)
  • Cytokine blockers (IL-1, IL-6, IL-17, TNFa)
61
Q

biological therapies (biologics) used for

A

Moderate to severe RA patients to slow disease progression

May be combined with DMARDs

62
Q

how many anti TNF therapies are licensed in the UK

A

5

all work in different ways

  • Infliximab binds soluble TNFa
  • —Prevent cytokine interacting with receptors – inhibit pathway
  • Etanercept binds and blocks TNF receptor
  • —Can bind to receptor – inhibit pathway
63
Q

effect of anti-TNF therapies

A

Patients can expect at least 20% clinical improvement
- due to inhibition of pathway either at cytokine interacting with receptor or receptor blocked

Often combined with methotrexate

64
Q

similarities and differenced between RA and periodontitis

A

both associated with destruction of bone

but perio trigger

  • Change in bacterial number or composition; Or gene expression; Or Virulence factors; Or Infection
  • —Consequence block inflammatory pathways that are preventing bacteria travelling through body

Rheumatoid - autoimmune

65
Q

what drives bone destruction in perio?

A

cytokines

  • elevated levels of cytokines in gingival tissues
  • Regulate immune-mediated bone destruction
66
Q

basic aim of vaccination

A

stimulate adaptive immunity and generate long-term immunological memory

67
Q

describe simply how vaccination is achieved

A

exposing our immune system to microbial antigens without causing disease

68
Q

what are conventional immunosuppressant drugs used to treat

A

wide-range of conditions

Corticosteroids
NSAIDs
Methotrexate

69
Q

what do targeted biological therapies do

A

harness the specificity of antibodies to target and block pathological inflammatory pathways